Canaccord analyst Jason Mills strongly recommended investors add to STAAR Surgical positions as he reiterated it as a top small-cap pick for 2019. The analyst believes the company will produce elite revenue growth and gross margin in 2019 and possibly deliver upside to 2019 after “crushing expectations” in 2018. Mills noted the company is expanding production and augmenting its commercial footprint globally in preparation for an enormous, expected wave of ICL adoption both near and long-term. Mills reiterated his Buy rating and $40 price target on STAAR Surgical shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.